Search Bar & Filters
Found 70 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are evaluating 177Lu-PSMA as a systemic adjuvant treatment for men with high and very high risk prostate cancer who have completed radical locoregional teleradiotherapy and hormone therapy. This phase 2 clinical trial aims to assess the treatments effectiveness in preventing cancer progression in this population, with no signs of cancer spread on recent radiological tests. The study includes two groups one receives a single dose of 177Lu-PSMA along with standard hormone therapy, while the control group receives only the standard hormone therapy. The single administration of 7.4 GBq of lutetium 177Lu vipivotide tetraxetan is given during the intervention phase. Both groups continue with standard hormone therapy throughout the study. Participants take part for one day during the intervention phase and then enter a five-year observation period. Researchers assess treatment effectiveness at 2 and 5 years after treatment, along with biochemical and radiological progression-free survival, time until next treatment, adverse events, and quality of life. Monitoring includes regular evaluations during the follow-up to track health status and any side effects.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are evaluating MK-1045, an immunotherapy, for treating two types of non-Hodgkin lymphoma NHL follicular lymphoma FL, which grows slowly, and diffuse large B-cell lymphoma DLBCL, which grows quickly. NHL is a cancer of the lymphatic system causing swollen lymph nodes. The study aims to learn about the safety and tolerability of MK-1045 and whether it helps reduce or eliminate these lymphomas. Participants are randomly assigned to one of four groups receiving MK-1045 in different doses and methods intravenous IV infusion or subcutaneous SC injection. Treatment continues for up to approximately one year or until participants stop. The study includes phases 1b and 2 and involves optimizing doses and schedules, including longer dosing intervals and subcutaneous administration. During the study, participants will have regular assessments including monitoring for adverse events, response to treatment using the Lugano Response Criteria, and measuring drug levels in the body. Researchers will track safety up to about 49 months and monitor discontinuation due to side effects for up to 12 months. Tumor tissue samples and other laboratory tests will also be collected to understand treatment effects. The total participation can last several years with ongoing evaluations.
Actively Recruiting
Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are evaluating ASP5541, a new form of abiraterone acetate given by muscle injection, in men with advanced prostate cancer. The study compares ASP5541, with or without prednisoneprednisolone, to standard abiraterone acetate tablets plus prednisoneprednisolone. It aims to assess the safety and effectiveness of ASP5541 in men with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer who have not previously received androgen receptor pathway inhibitors. Participants are assigned to one of three groups men with metastatic castration-resistant prostate cancer receive either ASP5541 plus prednisoneprednisolone or abiraterone acetate plus prednisoneprednisolone men with metastatic hormone-sensitive prostate cancer receive either ASP5541 alone or abiraterone acetate with prednisoneprednisolone and Japanese men with either cancer type receive ASP5541 with prednisoneprednisolone. ASP5541 is administered by injection every 12 weeks, prednisoneprednisolone is taken orally once or twice daily depending on cancer type, and abiraterone acetate is taken daily as tablets. All participants continue standard androgen deprivation therapy. During the study, participants will have regular clinic visits for health monitoring and safety checks, with some checking blood pressure weekly at home. Imaging scans and laboratory tests will assess cancer progression and treatment effects. Researchers will measure outcomes such as prostate-specific antigen levels, safety events, testosterone suppression, and cancer progression. The study includes long-term follow-up for up to 84 months and aims to provide detailed information on the safety and efficacy of ASP5541 compared to existing treatments.
Actively Recruiting
Researchers are studying the effects of AZD0120, an autologous dual-targeting CAR-T therapy aimed at BCMA and CD19, compared with autologous stem cell transplant ASCT in people newly diagnosed with multiple myeloma who are eligible for transplant. This open-label, randomized Phase III trial aims to measure progression-free survival and the rate of minimal residual disease negative complete response over up to 13 years. Participants are assigned to one of two treatment groups. Arm A receives lymphodepletion with cyclophosphamide and fludarabine over three days, followed by a single infusion of AZD0120 CAR-T cells, then up to two years of lenalidomide maintenance therapy. Arm B receives high-dose melphalan conditioning for 24 to 48 hours followed by ASCT and then the same lenalidomide maintenance regimen for up to two years. The study includes a long-term follow-up period lasting up to 15 years after the last AZD0120 infusion. Throughout the study, participants undergo regular monitoring, including assessments of disease progression and response according to established criteria. Researchers evaluate outcomes such as progression-free survival, complete and overall response rates, duration of response, and safety over approximately 13 years. Participants may expect study visits and evaluations aligned with treatment and follow-up schedules to track their health and treatment effects during this extended period.
1-10 of 70
1